321 HARRISON AVENUE, BOSTON, MA
2026 Annual Meeting Results; Three Directors Elected at Monte Rosa Therapeutics
Announces First Quarter 2026 Financial Results and Business Updates
Annual Report to Security Holders
Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
SVP Edmund Dunn Retirement; Matthew Bowen Named Successor
Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics Terminates ATM Prospectus Effective January 7, 2026
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
Submission Upload
Correspondence